Scientific basis of experimental therapy in bladder cancer

**Location:** Room Vienna (Hall B2, level 0)

**Chairs:** N. Fujimoto, Kitakyushu (JP)  
M. Knowles, Leeds (GB)  
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

**Aims and objectives of this presentation**
Transcription factors have been investigated in multiple tumours in order to improve chemotherapy. Targeting these transcription factors in urothelial cancer will be presented. In addition, the session will address the role of modulation of tumour metabolism and inhibition of steroid receptors in that tumour.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (±) are 3 minutes in length, followed by 3 minutes for discussion.

**924**

**Prediction of therapeutic resistance using ERBB2 expression status and Ki-67 labelling index in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach**

*By:* Inoue M.¹, Koga F.², Yoshida S.¹, Tanaka H.¹, Kobayashi S.¹, Yokoyama M.², Ishioka J.³, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fuji Y.¹, Kihara K.¹

*Institutes:* Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

**925**

**STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer**

*By:* Hayashi T.¹, Seiler R.², Bell R.², Ettinger S.², Wang K.², Goriki A.², Oo H.Z.², Awrey S.², Gust K.², Jaeger W.², Todenhöfer T.², Altamirano-Dimas M.², Matsubara A.¹, Collins C.², Black P.²

*Institutes:* Hiroshima University, Dept. of Urology, Hiroshima, Japan, ¹Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

**926**

**Transcription factor STAT3 is a potential therapeutic target in bladder cancer**

*By:* Schmid S.C., Yousef A., Sathe A., Horn T., Maurer T., Retz M., Gschwend J.E., Holm P.S., Nawroth R.

*Institutes:* Technische Universität München, Dept. of Urology, Munich, Germany

**927**

**Effective treatment of cisplatin-resistant bladder cancer using a glycosaminoglycan binding malaria protein**

*By:* Seiler R.¹, Oo H.¹, Lee S.¹, Tortora D.¹, Kumar G.¹, Chris W.¹, Clausen T.M.², Agerbæk M.O.², Gustavsson T.², Rich J.R.², Babcock J.², Black P.C.², Salanti A.², Daugaard M.¹

*Institutes:* University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Centre For Medical Parasitology, Dept. of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen, Denmark, ³Centre For Drug Research and Development, Dept. of Pharmaceutical Sciences, Vancouver, Canada, ⁴University of British Columbia, Dept of Urologic Sciences, Vancouver, Canada

**928**

**Androgen receptor signals reduce sensitivity to cisplatin in bladder cancer cells**

*By:* Kashiwagi E.¹, Ide H.², Kawahara T.², Reis L.², Eto M.¹, Miyamoto H.², Baras A.²

*Institutes:* Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Johns Hopkins School of Medicine, Dept. of Pathology, Baltimore, United States of America
**Poster Session 73**

*929*  
**Targeting lactate transporters for the treatment of urothelial carcinoma**  
**By:** Todenhöfer T.1, Seiler R.1, Stewart C.2, Moskalev L.1, Gao J.1, Ladar S.1, Kanyabi A.1, Al Nakouzi N.1, Hayashi T.1, Choi S.1, Wang Y.1, Frees S.1, Daugaard M.1, Zarni Ooh H.1, Hennenlotter J.2, Bedke J.2, Fazli L.1, Stenzl A.2, Black P.1  
**Institutes:** University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2  
Eberhard-Karls-Universität, Dept. of Urology, Tübingen, Germany

*930*  
**The PCNA targeting peptide drug ATX-101 enhances the efficacy of intravenous chemotherapy for muscle-invasive bladder cancer in an orthotopic rat bladder model**  
**By:** Blindheim A.J.1, Seggaard C.D.2, Gederaa O.2, Viset T.3, Arum C.-J.1, Otterlei M.2  
**Institutes:** St. Olav's Hospital, University Hospital of Trondheim, Dept. of Surgery, Trondheim, Norway, 2The Norwegian University of Science and Technology, Dept. of Cancer Research and Molecular Medicine, Trondheim, Norway, 3St. Olav's Hospital, University Hospital of Trondheim, Dept. of Pathology, Trondheim, Norway

*931*  
**Synergistic antitumor effect of satraplatin and NVP-BEZ235 in cisplatin-resistant human bladder cancer cells**  
**By:** Yoon C.Y.1, Kong M.K.1, Ahn H.G.1, Kang S.G.1, Han J.H.1, Kang Y.J.1, Jang W.S.1, Lee J.S.2, Kim Y.S.1, Park H.S.1, Cho I.R.2, Cheon J.4, Choi Y.D.1  
**Institutes:** Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Cheil General Hospital and Women's Healthcare Center, Dankook University, College of Medicine, Dept. of Urology, Seoul, South Korea, 3National Health Insurance Service Ilsan Hospital, Dept. of Urology, Ilsan, South Korea, 4Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea, 5Inje University, Ilsan Paik Hospital, Dept. of Urology, Ilsan, South Korea

*932*  
**HYAL4: A novel molecular biomarker and determinant of bladder cancer using RT112 reporter cells**  
**By:** Hennig M.1, Lokeshwar S.2, Knapp J.3, Hupe M.1, Krammer M.1, Manoharan M.2, Merseburger A.1, Lokeshwar V.4  
**Institutes:** University Of Lübeck, Dept. of Urology, Lübeck, Germany, 2Miller-School of Medicine, Dept. of Urology, Miami, United States of America, 3University of Lübeck, Dept. of Urology, Lübeck, Germany, 4Medical College of Georgia, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America

*933*  
**Establishment of a new orthotopic in vivo examinable model of non-muscle invasive bladder cancer using RT112 reporter cells**  
**By:** Fragoulis A.1, Fera C.2, Schemmert S.2, Strick K.2, Anton M.3, Mähring M.4, Steitz J.4, Tolba R.4, Grosse J.O.2  
**Institutes:** 1Uniklinik RWTH Aachen, Dept. of Orthopaedic Surgery, Aachen, Germany, 2Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, 3TU Munich, Institute of Molecular Immunology and Experimental Oncology, Munich, Germany, 4Uniklinik RWTH Aachen, Institute for Laboratory Animal Science, Aachen, Germany

*934*  
**Tumour-suppressive microRNA-26a/b inhibit cancer cell migration and invasion through targeting collagen cross-linking enzyme, PLOD2 in bladder cancer**  
**By:** Miyamoto K.1, Seki N.2, Matsushita R.1, Yonemori M.1, Yoshino H.1, Goto Y.2, Kato M.2, Kurozumi A.2, Nakagawa M.1, Enokida H.1  
**Institutes:** Kagoshima University Graduate School of Medical and Dental Sciences, Dept. of Urology, Kagoshima, Japan, 2Chiba University Graduate School of Medicine, Dept. of Functional Genomics, Chiba, Japan

*935*  
**Potential role of an IRE1α/XBP1 inhibitor in preventing therapeutic failure of intravesical BCG in bladder cancer**  
**By:** Lewicki P.1, Liu H.1, Golomboks D.1, O'Malley P.1, Cubillos-Ruiz J.2, Scherr D.1  
**Institutes:** Weill Cornell Medical College, Dept. of Urology, New York, United States of America, 2Weill Cornell Medical College, Dept. of Obstetrics and Gynecology, New York, United States of America
* Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer

By: Boormans J.L.¹, Naipal K.A.T.², Raams A.², Van Leenders G.J.L.H.³, Kanaar R.⁴, Van Gent D.C.²

Institutes: ¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Genetics, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Radiation Oncology, Rotterdam, The Netherlands